0.77
-0.0251(-3.17%)
Currency In USD
Previous Close | 0.79 |
Open | 0.81 |
Day High | 0.82 |
Day Low | 0.73 |
52-Week High | 1.62 |
52-Week Low | 0.66 |
Volume | 481,033 |
Average Volume | 306,634 |
Market Cap | 32.18M |
PE | -1.92 |
EPS | -0.4 |
Moving Average 50 Days | 0.89 |
Moving Average 200 Days | 0.93 |
Change | -0.03 |
If you invested $1000 in SCYNEXIS, Inc. (SCYX) 10 years ago, it would be worth $11.61 as of October 08, 2025 at a share price of $0.768. Whereas If you bought $1000 worth of SCYNEXIS, Inc. (SCYX) shares 5 years ago, it would be worth $124.8 as of October 08, 2025 at a share price of $0.768.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
GlobeNewswire Inc.
Sep 30, 2025 12:00 PM GMT
No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-
SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
GlobeNewswire Inc.
Sep 04, 2025 12:30 PM GMT
Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s broad spectrum
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
GlobeNewswire Inc.
Aug 25, 2025 12:00 PM GMT
JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis